EN DE
Watch AnGes, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AnGes, Inc (AMGXF) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of AnGes, Inc stock $0.23, price $0.17, upside +38.1%, quality 40 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Japan

AI AnGes, Inc logo Thin data Nov 10, 2026

AnGes, Inc

AMGXF · US

Cheap enough by our rule, but weak company.

Get notified free when this changes
Revenue last quarter +22% vs. a year ago. 
Fair value $0.2336 · Fairly valued 
Quality 40/100 
Expensive Growth (revenue 5y +85.3 %/yr in USD) 
Mixed vs. peers (3/7) 
Negative free cash flow 
Narrow moat 12/100
Thin data 
EstimatePrice via web search⚠ Thinly traded
Watch AnGes, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$5.40 $0.1574 Fair Value $0.2336 Jan 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.1574 – $5.40 · fair‑value band $0.1752 – $0.2920 · the $0.1691 price screens below the $0.2336 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow AnGes in your weekly email

Every Wednesday you see whether AnGes is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AnGes, Inc. engages in the research and development of gene-based medicines.

Show moreShow less

It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017.

The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.

Stock analysis

AnGes, Inc (AMGXF) currently trades at $0.1691, while our estimate is $0.2336, so the stock looks roughly fairly valued today (gap 27.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.1752 (bear) to $0.2920 (bull), the price of $0.1691 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

AnGes, Inc reported revenue of ¥874M in FY2025 versus ¥64.1M in FY2021, a compound +92.1%/yr. Reported net income was −¥5.1B in FY2025.

Key figures

Market cap $144M Micro · P/S ratio 0.15 · EPS (TTM) $−0.7900 · Return on equity −215% · Return on assets (EBIT) −81.4% (5-year average) · Operating margin −582% · Revenue (TTM) ¥962M · Revenue growth (YoY) +22.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 38%, AMGXF screens cheaper than that median.

Fair Value

Bear $0.1752 Fair Value $0.2336 Bull $0.2920
Price $0.1691 · Upside +38.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 79
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 97
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 33
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+35.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+137.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13,999.2% (2020) → −588.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch AMGXF, get fair value alerts →

Compare AnGes, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside +38.1% · Top 25%
Profitability
Return on assets −94.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 22.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.27× · Priciest 25%
P/S (12 months) 23.24× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)84 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs AMGXF
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs AMGXF
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs AMGXF
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs AMGXF
argenx SE ARGX $960.04 $908.40 −5% vs AMGXF
CSL Limited CSL A$202.52 A$185.51 −8% vs AMGXF
Moderna, Inc MRNA $223.37 $139.99 −37% vs AMGXF
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs AMGXF
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs AMGXF
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs AMGXF

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AnGes, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AnGes, Inc Fair Value". https://www.fairvalue-calculator.com/stock/AMGXF

Frequently asked questions

Is AnGes, Inc (AMGXF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.2336 versus a price of $0.1691, about +38% upside (fairly valued).
What is the fair value of AMGXF?
Our estimate for AnGes, Inc is $0.2336 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.1691.
What is the quality score of AMGXF?
AnGes, Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AnGes, Inc (AMGXF)?
Our calculated price target is the estimate of $0.2336 (as of Nov 10, 2026). Cautious scenario $0.1752, optimistic scenario $0.2920. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the AnGes, Inc stock forecast for 2026?
Our estimate puts fair value at $0.2336, about +38% upside versus a price of $0.1691 (fairly valued). Cautious scenario $0.1752, optimistic scenario $0.2920. The calculation is refreshed regularly with new filings.
What is the revenue of AnGes, Inc (AMGXF)?
AnGes, Inc reported trailing-twelve-month revenue of about ¥962M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of AnGes, Inc (AMGXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AnGes, Inc it is $0.2336 per share (as of Nov 10, 2026), against a price of $0.1691.
Is AnGes, Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AMGXF trades below its calculated fair value: price $0.1691, fair value $0.2336, a gap of about +38% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMGXF?
No. The price is what the market pays today ($0.1691); the fair value is what the company's own numbers justify ($0.2336). For AnGes, Inc the two are $0.0645 per share apart. That gap is exactly why we show both numbers side by side.
How much is AnGes, Inc worth?
The market values AnGes, Inc at about $144M (market capitalisation, as of Nov 10, 2026). Per share that is $0.1691; our models calculate a fair value of $0.2336 per share.
What do the bullish and bearish scenarios say about AMGXF?
Our models span a range for AnGes, Inc: cautious scenario $0.1752, base $0.2336, optimistic $0.2920 per share (as of Nov 10, 2026, price $0.1691). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AnGes, Inc (AMGXF)?
Balance-sheet figures for AnGes, Inc (as of Nov 10, 2026): return on equity −214.6%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
Which stocks are comparable to AnGes, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AnGes, Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.1691, calculated fair value $0.2336 (+38%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. AnGes, Inc currently trades 28% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AnGes, Inc (AMGXF)?
The closing price on Nov 13, 2026 was $0.1691. Our estimate is $0.2336, about +38% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AnGes, Inc right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.1752). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of AnGes, Inc

How large is the market capitalisation of AnGes, Inc (AMGXF)?
The market capitalisation of AnGes, Inc is $144M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AnGes, Inc (AMGXF)?
The price-to-sales ratio of AnGes, Inc is 0.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AnGes, Inc (AMGXF)?
Earnings per share at AnGes, Inc are $−0.7900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of AnGes, Inc (AMGXF)?
The return on equity (ROE) of AnGes, Inc is −215% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AnGes, Inc (AMGXF)?
On an EBIT basis the return on assets of AnGes, Inc is −81.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AnGes, Inc (AMGXF)?
The operating margin of AnGes, Inc is −582% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AnGes, Inc (AMGXF)?
Revenue at AnGes, Inc is growing 22.0% versus a year earlier (3y avg +137%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does AnGes, Inc (AMGXF) generate?
The free cash flow of AnGes, Inc is −¥5.8B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch AnGes, Inc in the live analysis

One click puts AnGes, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.